Impedance Spectroscopy in Detection of Obstetric Anal Sphincter Injuries

March 3, 2020 updated by: OASIS Diagnostics S.A.

Evaluation of the Effectiveness and Safety of Impedance Spectroscopy Device in Detecting Sphincter Injuries in Women After Natural Delivery

The main purpose of the study is to evaluate the effectiveness and safety of the impedance spectroscopy device prototype in detection of anal sphincter injuries in women in the early postpartum period. The study is prospective. The study group comprises 24 patients; included in it 6-8 weeks after natural delivery. The planned participation of each patient in the study is up to 4 weeks and three visits will take place at that time.

After obtaining written consent, at the screening visit (V0) each patient will undergo a physical examination, blood samples for laboratory tests and stool samples for calprotectin concentration assessment will be collected.

On the second visit (V1), after the final verification of inclusion/exclusion criteria, impedance spectroscopy using tested device will be performed in each patient, the electrical impedance of pelvic floor muscles will be measured and the degree of anal sphincter damage will be evaluated. Full gynecological and proctological examination (including a gynecological speculum, two-handed examination, rectal examination and anoscopy) will be carried out.

On the third visit (V2), two reference diagnostic tests (with evidenced effectiveness and safety), transanal ultrasonography and anorectal manometry, will be conducted. The collected data will be used to select the optimal therapeutic method for each participant individually.

Study Overview

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lodzkie
      • Łódź, Lodzkie, Poland, 95-070
        • Centrum Medyczne Byc Kobieta s.c.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • after natural delivery and post-partum period (6-8 weeks after delivery)
  • physiological pregnancy
  • observed a perianal tear of grade 1-4 in the OASIS classification
  • signed informed consent

Exclusion Criteria:

  • presence of acute diseases during treatment
  • presence of chronic diseases untreated or insufficiently treated (e.g. poorly controlled hypertension),
  • presence of diseases, with symptoms of fecal incontinence,
  • previous proctological operations,
  • the presence of inflammatory bowel diseases in the stage of exacerbation,
  • treatment in the last year due to severe, progressive, uncontrolled cardiac, pulmonary, nephrological, infectious or psychiatric disease, which course could affect the patient's risk due to participation in study,
  • significant deviations from the norm in a physical examination during V0 visit or laboratory tests taken during the same visit,
  • significant disease symptoms so far undiagnosed and reported during the V0 visit
  • presence or suspected malignant disease or previous oncological treatment during the last 5 years,
  • presence of a cardiac stimulator or cardioverter-defibrillator,
  • severe surgery or severe trauma in the last year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Impedance spectroscopy

24 women will be included in the study and divided into two subgroups.

12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.

Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.

The planned interventions are:

  • Blood and faeces tests
  • Impedance spectroscopy test
  • Full gynecological and proctological examination
  • Transanal ultrasonography
  • Anorectal manometry
During V0 - Laboratory tests, particularly for calprotectin concentration assessment
During V1 - the electrical impedance of pelvic floor muscles will be measured
During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anal sphincters injury
Time Frame: 8 weeks

Assessed by subsequent measures:

  1. Sphincter continuity in physical examination,
  2. Sphincter tension in physical examination,
  3. OASIS classification of perineal tears in transanal ultrasonography
  4. Starck scale for classification of anal sphincter injuries in transanal ultrasound (0-16 scale, no defect - 0; maximum - 16, means severe damage of both sphincters on a considerable length and circumference)
  5. Norderval scale for classification of anal sphincter injuries in transanal ultrasound (0-7 scale, no defect - 0, 7 is the maximal damage of both anal sphincters)
  6. anorectal manometry assessment to measure anal sphincters function

All measurements are used to estimate the presence, extent and severity of anal sphincter injury.

The main aim of the study is to establish whether the extension and severity of obstetric anal sphincter injury can be precisely assessed with parameters calculated from pelvic floor muscles using impedance spectroscopy.

8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse events
Time Frame: 8 weeks
Evaluation of the frequency and intensity of adverse events associated with the use of the new diagnostic method.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Grzegorz Surkont, MD, PhD, Centrum Medyczne Byc Kobieta s.c.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 4, 2019

Primary Completion (ACTUAL)

October 30, 2019

Study Completion (ACTUAL)

December 23, 2019

Study Registration Dates

First Submitted

October 9, 2018

First Submitted That Met QC Criteria

December 5, 2018

First Posted (ACTUAL)

December 10, 2018

Study Record Updates

Last Update Posted (ACTUAL)

March 4, 2020

Last Update Submitted That Met QC Criteria

March 3, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1/1/2018 (Sep 8)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delivery, Obstetric

Clinical Trials on Blood and faeces tests

Subscribe